NHLBI Media Availability: NIH Ends Transcranial Doppler (TCD) with Transfusions Changing to Hydroxyurea (TWiTCH) Clinical Trial Due to Early Results

Press Releases November 19, 2014 NIH Ends Transcranial Doppler (TCD) with Transfusions Changing to Hydroxyurea (TWiTCH) Clinical Trial Due to Early Results The National Heart, Lung, and Blood Institute has ended the Transcranial Doppler (TCD) with Transfusions Changing to Hydroxyurea (TWiTCH) clinical trial early in agreement with the recommendations of the Data and Safety Monitoring Board (DSMB). The results of this study show that hydroxyurea is not inferior to (that is, no worse than) regular blood transfusions in lowering TCD blood velocities in children with sickle cell disease who are at high risk for stroke. Related links: Health Topic: What Is a Sickle Cell Anemia? You received this message because you are subscribed to "Press Releases" from the National Heart, Lung, and Blood Institute. Related information can be found on the NHLBI News and Resources home page. Questions? Contact us STAY CONNECTED:    Manage Subscriptions or Account Preferences  |  Delete Account  |  Help The "Delete Account" link will unsubscribe you from every topic and delete your email address from the system.  To unsubscribe from select topics, click on "Manage Subscriptions or Account Preferences." If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com.  If you have questions or comments about other NHLBI programs or activities, please contact nhlbiinfo@nhlbi.nih.gov. This service is provided to you at no charge by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health. GovDelivery, Inc. sending on behalf of The National Heart, Lung, and Blood Institute · P.O. Box 30105 · Bethesda, MD 20824 · 301-592-8573 TTY: 240-629-3255

Tweet

Postingan terkait:

— Thursday, November 20, 2014 — Add Comment